Roivant Sciencesと第一三共が広範なパイプラインパートナーシップ契約

Roivant Sciences

Roivant Sciencesと第一三共が広範なパイプラインパートナーシップ契約

AsiaNet 76835(2379)

【ニューヨーク2018年12月19日PR Newswire=共同通信JBN】Roivant Sciencesは19日、治験用医薬品のライセンス供与を促進するため、第一三共株式会社(以下「第一三共」)と提携したと発表した。合意の条項によると、Roivantは開発段階に応じてあらかじめ決まった条件で第一三共から特定の開発計画の専用実施権を取得するオプションを獲得する。


Roivant Pharma社長のマユク・スカトメ博士は「このパートナーシップを生み出すために第一三共チーム全体と協力するのは光栄であり、喜びである。これが将来、Roivantと他の革新的バイオ医薬品企業とのプラットフォーム提携のモデルになるように望む。今後数カ月、数年で、第一三共の素晴らしい研究開発力により、有望な医薬品の開発を加速することを期待している」と語った。

▽Roivant Sciencesについて


詳細は を参照。


第一三共グループは、先進市場、新興市場の双方の患者の多様な、まだ満たされない医療ニーズに対応するため、革新的な医薬品の創出と供給に専心している。第一三共は100年を超える科学的経験と20カ国以上でのプレセンスがあり、世界中の1万5000人の従業員とともに、豊富な革新の伝統と有望な新薬の活発な開発を活用し、人々に貢献している。高血圧と血栓障害の強力なポートフォリオに加え「がんに強みを持つ先進的グローバル創薬企業」を目指す同グループの2025年ビジョンの下で、第一三共の研究開発は主として、がん免疫を含むがんの新たな治療法に注力し、疼痛管理、神経変性疾患、心臓・腎臓疾患、他の希少疾患などの新たな領域も重視している。詳細は を参照。


Paul Davis

Head of Communications

Roivant Sciences

(646) 495-5310

Roivant Sciences and Daiichi Sankyo Enter into Broad Pipeline Partnership


NEW YORK and BASEL, Switzerland, Dec. 19, 2018 /PRNewswire=KYODO JBN/ --

Roivant Sciences today announced that it has entered into a collaboration with

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) to facilitate the

out-licensing of investigational medicines. Under the terms of the agreement,

Roivant will have the option to obtain exclusive licenses for certain

development programs from Daiichi Sankyo on prespecified terms contingent on

phase of development.

Daiichi Sankyo has a wide range of compounds in development. Medicines that

Roivant opts to license will be developed by new subsidiary companies within

the Roivant family.

"It has been an honor and a pleasure for us to work with the entire Daiichi

Sankyo team in the course of creating this partnership. I hope this can be a

model for platform collaborations between Roivant and other innovative

biopharmaceutical companies in the future," said Dr. Mayukh Sukhatme, President

of Roivant Pharma. "We look forward to accelerating the development of

promising medicines from the impressive R&D engine at Daiichi Sankyo in the

months and years ahead."

About Roivant Sciences

Roivant aims to improve health by rapidly delivering innovative medicines and

technologies to patients. We do this by building Vants – nimble,

entrepreneurial biotech and healthcare technology companies with a unique

approach to sourcing talent, aligning incentives, and deploying technology to

drive greater efficiency in R&D and commercialization.

For more information, please visit

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative

pharmaceutical products to address diversified, unmet medical needs of patients

in both mature and emerging markets. With over 100 years of scientific

expertise and a presence in more than 20 countries, Daiichi Sankyo and its

15,000 employees around the world draw upon a rich legacy of innovation and a

robust pipeline of promising new medicines to help people. In addition to a

strong portfolio of medicines for hypertension and thrombotic disorders, under

the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive

Advantage in Oncology," Daiichi Sankyo research and development is primarily

focused on bringing forth novel therapies in oncology, including

immuno-oncology, with additional focus on new horizon areas, such as pain

management, neurodegenerative diseases, heart and kidney diseases, and other

rare diseases. For more information, please visit:


Paul Davis

Head of Communications

Roivant Sciences

CONTACT: Paul Davis, (646) 495-5310